This is a working overview of HGF/c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
== Biofilm characteristics == The formation of the cellulose pellicle at the surface of the broth yields a product with unique characteristics that both bacteria and consumers find advantageous. Upon inoculation into the culture, bacteria such as Acetobacter immediately begin pulling glucose molecules together outside of the cell and joining them via β(1-4) linkages to form long, slender structures extending from their cell membranes called fibrils. The nanocellulose composing these fibrils demonstrates great strength and stability while still allowing hydrophilic interactions and biocompatibility, making it a great resource for the culture to use. A variety of inter and intramolecular bonding events join numerous fibrils together into the final, much larger structures known as microfibrils; because of the integrity of the microfibrils and the organized, linear nature of cellulose bonds, the resulting biofilm can also be referred to as a matrix or mat. This biofilm is a natural defense mechanism for the co-culture, and can withstand extreme conditions such as temperature and UV radiation. Two additional characteristics of the nanofibril cellulose SCOBY—its high purity and crystallinity—are currently a target in biomedical research in the formation of biocompatible tissue scaffolds, cardiovascular components such as blood vessels, bone grafts, and connective tissue replacements. The nanocellulose fibrils can also be extracted via acid hydrolysis and used in the food packaging, clothing, and wastewater treatment industries.
A large factor controlling the redox budget of early Earth's atmosphere is the rate of atmospheric escape of H2 after Earth's formation. Atmospheric escape – common to young, rocky planets — occurs when gases in the atmosphere have sufficient kinetic energy to overcome gravitational energy. It is generally accepted that the timescale of hydrogen escape is short enough such that H2 made up < 1% of the atmosphere of prebiotic Earth, but, in 2005, a hydrodynamic model of hydrogen escape predicted escape rates two orders of magnitude lower than previously thought, maintaining a hydrogen mixing ratio of 30%. A hydrogen-rich prebiotic atmosphere would have large implications for Miller–Urey synthesis in the Hadean and Archean, but later work suggests solutions in that model might have violated conservation of mass and energy. That said, during hydrodynamic escape, lighter molecules like hydrogen can "drag" heavier molecules with them through collisions, and recent modeling of xenon escape has pointed to a hydrogen atmospheric mixing ratio of at least 1% or higher at times during the Archean. Taken together, the view that early Earth's atmosphere was weakly reducing, with transient instances of highly-reducing compositions following large impacts is generally supported.
The vast majority of insulin used worldwide is biosynthetic recombinant human insulin or its analogues. Recently, another recombinant approach has been used by a pioneering group of Canadian researchers, using an easily grown safflower plant, for the production of much cheaper insulin. Recombinant insulin is produced either in yeast (usually Saccharomyces cerevisiae) or E. coli. In yeast, insulin may be engineered as a single-chain protein with a KexII endoprotease (a yeast homolog of PCI/PCII) site that separates the insulin A chain from a C-terminally truncated insulin B chain. A chemically synthesized C-terminal tail containing the missing threonine is then grafted onto insulin by reverse proteolysis using the inexpensive protease trypsin; typically the lysine on the C-terminal tail is protected with a chemical protecting group to prevent proteolysis. The ease of modular synthesis and the relative safety of modifications in that region accounts for common insulin analogs with C-terminal modifications (e.g. lispro, aspart, glulisine). The Genentech synthesis and completely chemical synthesis such as that by Bruce Merrifield are not preferred because the efficiency of recombining the two insulin chains is low, primarily due to competition with the precipitation of insulin B chain.
=== Names === Diamorphine is the international nonproprietary name and the British Approved Name. Other synonyms for heroin include: diacetylmorphine, and morphine diacetate. Heroin is also known by many street names including Big H, Black Tar, Chiva, Hell Dust, Horse, Negra, Smack, Thunder, dope, H, smack, junk, skag, brown, and unga among others. Whoonga (or wonga), nyaope and sugars are South African street names for heroin.
==== Monazite age mapping ==== Estimated ages are calculated across the compositional map by analysing the concentration of Th, Pb and U by the total-Pb dating method. The result is then used to generate an age map which approximately identifies all the age domains.
Sources: en.wikipedia.org
== Adverse effects == Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain. Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.
=== Chemical === The chemistry of nihonium is expected to be very different from that of thallium. This difference stems from the spin–orbit splitting of the 7p shell, which results in nihonium being between two relatively inert closed-shell elements (copernicium and flerovium). Nihonium is expected to be less reactive than thallium, because of the greater stabilisation and resultant chemical inactivity of the 7s subshell in nihonium compared to the 6s subshell in thallium. The standard electrode potential for the Nh+/Nh couple is predicted to be 0.6 V. Nihonium should be a rather noble metal. The metallic group 13 elements are typically found in two oxidation states: +1 and +3. The former results from the involvement of only the single p electron in bonding, and the latter results in the involvement of all three valence electrons, two in the s-subshell and one in the p-subshell. Going down the group, bond energies decrease and the +3 state becomes less stable, as the energy released in forming two additional bonds and attaining the +3 state is not always enough to outweigh the energy needed to involve the s-electrons. Hence, for aluminium and gallium +3 is the most stable state, but +1 gains importance for indium and by thallium it becomes more stable than the +3 state. Nihonium is expected to continue this trend and have +1 as its most stable oxidation state. The simplest possible nihonium compound is the monohydride, NhH. The bonding is provided by the 7p1/2 electron of nihonium and the 1s electron of hydrogen.
In March 2016, Taco Bell introduced private beta testing of an artificial intelligence bot on the messaging platform Slack designed to take orders of select menu items from local Taco Bell locations and have the orders delivered. Taco Bell planned to have a wider roll-out of this functionality in the coming months. Previously, Taco Bell's hot sauces were only available in packets at the chain itself. In February 2014, Taco Bell made its hot sauces available at grocery stores, sold in bottles. These would be followed by further grocery store products including chips in May 2018 and shredded cheese in 2019. In September 2016, Taco Bell opened a pop-up in New York City in the SoHo, Manhattan area called the Taco Bell VR Arcade. Taco Bell and VR fans could demo PlayStation VR, games, and food. In 2016, Taco Bell debuted a modular restaurant constructed from five reclaimed shipping containers at the South by Southwest (SXSW) festival in Austin, Texas. Following its successful reception, the structure was permanently relocated to South Gate, California, where it commenced operations as a standard franchise location in 2017. The restaurant features Taco Bell's full menu, with outdoor seating, a walk-up window, and a drive-thru, but no indoor seating unlike regular Taco Bell locations. Taco Bell announced plans in November 2017 to open 300 more urban and Cantina-style locations by 2022, with 50 to be located about New York City's five boroughs. In 2019, Taco Bell opened a pop-up hotel called "The Bell: A Taco Bell Hotel and Resort" for one weekend in August.
== The TRAIL receptors as a drug target == In clinical trials only a small proportion of cancer patients responded to various drugs that targeted TRAIL death receptors. Many cancer cell lines develop resistance to TRAIL and limits the efficacy of TRAIL-based therapies.
David L. Eaton (born August 15, 1952) is an American toxicologist and professor Emeritus at the University of Washington (UW). His work focuses on risk assessment, gene-environment interactions, environmental carcinogenesis, and xenobiotic biotransformation. Over his career, Eaton has chaired committees for the National Academies of Sciences, Engineering, and Medicine (NASEM), held academic administration positions at the University of Washington, and presided over the Society of Toxicology (SOT).
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.